Search for Clinical Trial Results

Sponsored By

Langerhans Cell Histiocytosis - 3 Studies Found

Status Study
Completed Study Name: Mirdametinib in Histiocytic Disorders
Condition: Langerhans Cell Histiocytosis (LCH)
Date: 2025-11-04
Interventions: Mirdametinib is administered at a dose of 2 mg/m2, twice a day (BID) with a maximum dose of 4 mg BID on a continuous daily schedule.Consecu
Completed Study Name: LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study
Condition: Langerhans Cell Histiocytosis
Date: 2025-11-04
Interventions: Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
COMPLETED Study Name: Denosumab for the Treatment of Adult LCH
Condition: Langerhans Cell Histiocytosis
Date: 2025-11-04
Interventions: As already described in arm description